Related Experiment Video
Updated: Sep 15, 2025

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
Published on: August 26, 2025
Sex Differences Among Patients Treated With Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary
Cze Ci Chan1, Bárbara Lacerda Teixeira2, Jenny Z Yang3
1Division of Cardiology, Linkou Medical Center Chang Gung Memorial Hospital Taoyuan City Taiwan.
Abstract:
Studies have shown sex differences in the outcomes of chronic thromboembolic pulmonary hypertension (CTEPH) and in patients who have undergone pulmonary endarterectomy. Limited data exist regarding outcomes of balloon pulmonary angioplasty (BPA) for female versus male subjects. In this analysis cohort, a total of 767 sessions of BPA were performed on 144 patients of which 83 (58%) were female. There were no differences in age, body mass index and comorbidities between males and females. However, females had worse baseline functional class, higher median N-terminal pro-brain natriuretic peptide and a shorter 6-min walk test. At baseline, males were more likely to be on pulmonary hypertension (PH) medical treatment before BPA (92% vs 76%, p = 0.008), and females had significantly higher pulmonary vascular resistance (PVR) (5.5 ± 3.0 wu vs 3.9 ± 1.9 wu, p < 0.001). After BPA, the improvements in mean pulmonary artery pressure and PVR from baseline were comparable in both groups. The requirement for PH medical therapy significantly reduced after BPA for males (92% vs. 80%, p = 0.008) but not for females. Functional class improved in both groups after BPA. There were no significant differences in complication rates per BPA session between male and female patients (9% and 12%, p = 0.104). Female CTEPH patients had a worse baseline clinical profile including higher PVR. Female patients were also more likely to remain on PH medical therapy after BPA. There were no significant differences observed in hemodynamic response to BPA and in complication rates between male and female patients.
More Related Videos
Related Concept Videos
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Pulmonary Embolism III: Nursing Management
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...

